Co-Diagnostics Inc. (NASDAQ: CODX) logged a significant share-price gain after it disclosed an advance in its PCR assay development plan aimed at the Bundibugyo ebolavirus. The company said the effort is being pursued through a collaborative strategy with its Indian joint venture, CoSara Diagnostics.
According to the company, the joint development arrangement is structured to address requirements for deploying diagnostic assays internationally, should the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda continue to spread or expand beyond its current footprint. CoSara's regional manufacturing and operational capabilities are cited as potential enablers of rapid deployment initiatives in certain international markets, though the company emphasized these actions would remain subject to applicable regulatory requirements.
The development program encompasses evaluation of both Bundibugyo virus (BDBV)-specific assays and pan-Ebola configurations that are designed to detect multiple ebolavirus species. In parallel, the company is exploring workflow setups intended for point-of-care and decentralized testing environments that would operate on the Co-Dx PCR point-of-care platform.
International health monitors have reported an escalation in cases tied to the current outbreak. On May 25, the World Health Organization reported that the BDBV outbreak - which the WHO Director-General declared a public health emergency of international concern on May 17, 2026 - has produced more than 900 suspected cases and roughly 220 suspected deaths. The WHO also stated that response operations are currently being outpaced by the epidemic.
Co-Diagnostics' chief executive, Dwight Egan, said the company is pleased with the program's development and that it will continue to observe the evolving situation closely.
The company also reiterated regulatory caveats for its Co-Dx PCR platform. The suite - which includes the PCR Home, PCR Pro, a companion mobile application, and associated tests - remains under review by the U.S. Food and Drug Administration and other regulatory bodies and is not yet available for sale.
Context for markets and users
- Diagnostics and biotechnology market participants will track assay progress and regulatory reviews that determine when products become commercially available.
- Public health and humanitarian response sectors could be affected by changes in diagnostic availability and regional manufacturing capacity.
- Investors in Co-Diagnostics responded quickly to the development news, driving the notable share-price increase.